
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1591522/publications.pdf Version: 2024-02-01



IFFEDEV D FSKO

#	Article	IF	CITATIONS
1	Multiplex genome editing of mammalian cells for producing recombinant heparin. Metabolic Engineering, 2022, 70, 155-165.	7.0	5
2	Cancer-cell-secreted miR-122 suppresses O-GlcNAcylation to promote skeletal muscle proteolysis. Nature Cell Biology, 2022, 24, 793-804.	10.3	29
3	Chondroitin sulfate enhances the barrier function of basement membrane assembled by heparan sulfate. Development (Cambridge), 2022, 149, .	2.5	5
4	Impaired mitophagy in Sanfilippo a mice causes hypertriglyceridemia and brown adipose tissue activation. Journal of Biological Chemistry, 2022, 298, 102159.	3.4	2
5	Beware, commercial chondroitinases vary in activity and substrate specificity. Glycobiology, 2021, 31, 103-115.	2.5	5
6	Calixarene-decorated liposomes for intracellular cargo delivery. Organic and Biomolecular Chemistry, 2021, 19, 6598-6602.	2.8	4
7	A Systems View of the Heparan Sulfate Interactome. Journal of Histochemistry and Cytochemistry, 2021, 69, 105-119.	2.5	44
8	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature, 2021, 593, 418-423.	27.8	151
9	Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate. Nature Chemical Biology, 2021, 17, 684-692.	8.0	14
10	Genome wide analysis of heparan sulfate assembly. FASEB Journal, 2021, 35, .	0.5	0
11	Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 4489.	3.7	2
12	Endothelial Heparan Sulfate Mediates Hepatic Neutrophil Trafficking and Injury during Staphylococcus aureus Sepsis. MBio, 2021, 12, e0118121.	4.1	8
13	Elongated neutrophil-derived structures are blood-borne microparticles formed by rolling neutrophils during sepsis. Journal of Experimental Medicine, 2021, 218, .	8.5	29
14	The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility. Journal of Biological Chemistry, 2021, 297, 101391.	3.4	10
15	Dissecting structure-function of 3-O-sulfated heparin and engineered heparan sulfates. Science Advances, 2021, 7, eabl6026.	10.3	23
16	Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions. Acta Neuropathologica, 2020, 139, 527-546.	7.7	23
17	A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia. Nature Communications, 2020, 11, 5998.	12.8	8
18	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell, 2020, 183, 1043-1057.e15.	28.9	860

#	Article	IF	CITATIONS
19	Prion protein post-translational modifications modulate heparan sulfate binding and limit aggregate size in prion disease. Neurobiology of Disease, 2020, 142, 104955.	4.4	5
20	An affinity chromatography and glycoproteomics workflow to profile the chondroitin sulfate proteoglycans that interact with malarial VAR2CSA in the placenta and in cancer. Glycobiology, 2020, 30, 989-1002.	2.5	16
21	ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9311-9317.	7.1	30
22	Chondrocytes respond to an altered heparan sulfate composition with distinct changes of heparan sulfate structure and increased levels of chondroitin sulfate. Matrix Biology, 2020, 93, 43-59.	3.6	13
23	An altered heparan sulfate structure in the articular cartilage protects against osteoarthritis. Osteoarthritis and Cartilage, 2020, 28, 977-987.	1.3	13
24	Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate. Biochemical Journal, 2020, 477, 3433-3451.	3.7	16
25	Proteomics-based screening of the endothelial heparan sulfate interactome reveals that C-type lectin 14a (CLEC14A) is a heparin-binding protein. Journal of Biological Chemistry, 2020, 295, 2804-2821.	3.4	18
26	Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease. Journal of Clinical Investigation, 2020, 130, 1350-1362.	8.2	32
27	ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2145-2156.	2.4	20
28	Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. Journal of Biological Chemistry, 2019, 294, 13292-13303.	3.4	15
29	Proteomic atlas of organ vasculopathies triggered by Staphylococcus aureus sepsis. Nature Communications, 2019, 10, 4656.	12.8	46
30	Plasma Proteome Signature of Sepsis: a Functionally Connected Protein Network. Proteomics, 2019, 19, e1800389.	2.2	17
31	ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. Journal of Lipid Research, 2019, 60, 1379-1395.	4.2	48
32	Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants. Glycobiology, 2019, 29, 582-592.	2.5	13
33	Regulation of eosinophil recruitment and allergic airway inflammation by heparan sulfate proteoglycan (HSPG) modifying enzymes. Experimental Lung Research, 2018, 44, 98-112.	1.2	10
34	Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy. Translational Neurodegeneration, 2018, 7, 6.	8.0	26
35	Cellular uptake of modified aminoglycosides. Journal of Antibiotics, 2018, 71, 142-145.	2.0	3
36	Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference. Connective Tissue Research, 2018, 59, 85-98.	2.3	9

#	Article	IF	CITATIONS
37	A mutant-cell library for systematic analysis of heparan sulfate structure–function relationships. Nature Methods, 2018, 15, 889-899.	19.0	71
38	The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biology, 2018, 71-72, 262-282.	3.6	36
39	Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase. Scientific Reports, 2018, 8, 11832.	3.3	11
40	Arylsulfatase K is the Lysosomal 2-Sulfoglucuronate Sulfatase. ACS Chemical Biology, 2017, 12, 367-373.	3.4	12
41	Whole-Genome Sequencing of Invasion-Resistant Cells Identifies Laminin $\hat{I}\pm 2$ as a Host Factor for Bacterial Invasion. MBio, 2017, 8, .	4.1	36
42	Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice. Scientific Reports, 2017, 7, 46576.	3.3	29
43	Targeting heparin and heparan sulfate protein interactions. Organic and Biomolecular Chemistry, 2017, 15, 5656-5668.	2.8	128
44	Delivery of Cargo to Lysosomes Using GNeosomes. Methods in Molecular Biology, 2017, 1594, 151-163.	0.9	6
45	Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain. Molecular Therapy, 2017, 25, 2743-2752.	8.2	10
46	Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Scientific Reports, 2017, 7, 9008.	3.3	101
47	PinAPL-Py: A comprehensive web-application for the analysis of CRISPR/Cas9 screens. Scientific Reports, 2017, 7, 15854.	3.3	75
48	Dendrimeric Guanidinoneomycin for Cellular Delivery of Bioâ€macromolecules. ChemBioChem, 2017, 18, 119-125.	2.6	8
49	Polymyxins facilitate entry into mammalian cells. Chemical Science, 2016, 7, 5059-5068.	7.4	6
50	Delivery of an active lysosomal enzyme using GNeosomes. Journal of Materials Chemistry B, 2016, 4, 5794-5797.	5.8	10
51	Glycan susceptibility factors in autism spectrum disorders. Molecular Aspects of Medicine, 2016, 51, 104-114.	6.4	36
52	Expanding the 3- <i>O</i> -Sulfate Proteome—Enhanced Binding of Neuropilin-1 to 3- <i>O</i> -Sulfated Heparan Sulfate Modulates Its Activity. ACS Chemical Biology, 2016, 11, 971-980.	3.4	57
53	Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo. Journal of Virology, 2016, 90, 412-420.	3.4	30
54	ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. Journal of Clinical Investigation, 2016, 126, 2855-2866.	8.2	186

JEFFREY D ESKO

#	Article	IF	CITATIONS
55	Loss of Corneal Epithelial Heparan Sulfate Leads to Corneal Degeneration and Impaired Wound Healing. , 2015, 56, 3004.		36
56	Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy. Science Translational Medicine, 2015, 7, 288ra76.	12.4	44
57	Role of the endothelial surface layer in neutrophil recruitment. Journal of Leukocyte Biology, 2015, 98, 503-515.	3.3	104
58	Small molecule antagonists of cell-surface heparan sulfate and heparin–protein interactions. Chemical Science, 2015, 6, 5984-5993.	7.4	21
59	Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-β. Cytokine, 2015, 72, 118-119.	3.2	21
60	Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nature Communications, 2015, 6, 6356.	12.8	360
61	Heparan Sulfate Modulates Neutrophil and Endothelial Function in Antibacterial Innate Immunity. Infection and Immunity, 2015, 83, 3648-3656.	2.2	30
62	GNeosomes: Highly Lysosomotropic Nanoassemblies for Lysosomal Delivery. ACS Nano, 2015, 9, 3961-3968.	14.6	17
63	Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nature Genetics, 2015, 47, 528-534.	21.4	111
64	Symbol Nomenclature for Graphical Representations of Glycans. Glycobiology, 2015, 25, 1323-1324.	2.5	818
65	Heparan Sulfate Regulates Hair Follicle and Sebaceous Gland Morphogenesis and Homeostasis. Journal of Biological Chemistry, 2014, 289, 25211-25226.	3.4	42
66	Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. Kidney International, 2014, 86, 932-942.	5.2	39
67	Podocyte-specific deletion of NDST1, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization in vivo. Kidney International, 2014, 85, 307-318.	5.2	19
68	Macromolecular Uptake of Alkylâ€Chainâ€Modified Guanidinoglycoside Molecular Transporters. ChemBioChem, 2014, 15, 676-680.	2.6	9
69	Endothelial and leukocyte heparan sulfates regulate the development of allergen-induced airway remodeling in a mouse model. Glycobiology, 2014, 24, 715-727.	2.5	18
70	The GPIHBP1–LPL Complex Is Responsible for the Margination of Triglyceride-Rich Lipoproteins in Capillaries. Cell Metabolism, 2014, 19, 849-860.	16.2	124
71	Heparan sulfate expression in the neural crest is essential for mouse cardiogenesis. Matrix Biology, 2014, 35, 253-265.	3.6	19
72	Reducing Macrophage Proteoglycan Sulfation Increases Atherosclerosis and Obesity through Enhanced Type I Interferon Signaling. Cell Metabolism, 2014, 20, 813-826.	16.2	65

#	Article	IF	CITATIONS
73	Xylose phosphorylation functions as a molecular switch to regulate proteoglycan biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15723-15728.	7.1	94
74	On Guanidinium and Cellular Uptake. Journal of Organic Chemistry, 2014, 79, 6766-6774.	3.2	71
75	Bioengineering murine mastocytoma cells to produce anticoagulant heparin. Glycobiology, 2014, 24, 272-280.	2.5	14
76	Heparan sulfate 3-O-sulfation: A rare modification in search of a function. Matrix Biology, 2014, 35, 60-72.	3.6	182
77	Demystifying Heparan Sulfate–Protein Interactions. Annual Review of Biochemistry, 2014, 83, 129-157.	11.1	610
78	Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I. Molecular Genetics and Metabolism, 2014, 112, 286-293.	1.1	13
79	Glycan-based biomarkers for mucopolysaccharidoses. Molecular Genetics and Metabolism, 2014, 111, 73-83.	1.1	67
80	Heparan sulfate deficiency disrupts developmental angiogenesis and causes congenital diaphragmatic hernia. Journal of Clinical Investigation, 2014, 124, 209-221.	8.2	53
81	Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. PLoS ONE, 2014, 9, e115662.	2.5	12
82	Loss of β-Catenin Induces Multifocal Periosteal Chondroma-Like Masses in Mice. American Journal of Pathology, 2013, 182, 917-927.	3.8	22
83	Aggregation-Mediated Macromolecular Uptake by a Molecular Transporter. ACS Chemical Biology, 2013, 8, 1383-1388.	3.4	20
84	Stable RAGE-Heparan Sulfate Complexes Are Essential for Signal Transduction. ACS Chemical Biology, 2013, 8, 1611-1620.	3.4	71
85	Hepatic Remnant Lipoprotein Clearance by Heparan Sulfate Proteoglycans and Low-Density Lipoprotein Receptors Depend on Dietary Conditions in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2065-2074.	2.4	69
86	Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. Journal of Clinical Investigation, 2013, 123, 2742-2751.	8.2	65
87	Nâ€sulfation of Cell Surface Heparan Sulfate Glycosaminoglycans is Critical for Podocyteâ€Matrix Interactions. FASEB Journal, 2013, 27, 523.14.	0.5	0
88	Functional Overlap Between Chondroitin and Heparan Sulfate Proteoglycans During VEGF-Induced Sprouting Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1255-1263.	2.4	62
89	A Genetic Model of Substrate Reduction Therapy for Mucopolysaccharidosis. Journal of Biological Chemistry, 2012, 287, 36283-36290.	3.4	21
90	Arylsulfatase G inactivation causes loss of heparan sulfate 3- <i>O</i> -sulfatase activity and mucopolysaccharidosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10310-10315.	7.1	61

#	Article	IF	CITATIONS
91	Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood, 2012, 120, 1742-1751.	1.4	80
92	Disease-specific non–reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nature Chemical Biology, 2012, 8, 197-204.	8.0	124
93	Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin. Metabolic Engineering, 2012, 14, 81-90.	7.0	67
94	Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology, 2012, 55, 277-286.	7.3	35
95	Molecular dissection of syndecanâ€1 mediated triglycerideâ€rich lipoprotein clearance. FASEB Journal, 2012, 26, 792.2.	0.5	0
96	Alteration of heparan sulfate 2â€Oâ€sulfation in endothelial cells enhances neutrophil infiltration in mice. FASEB Journal, 2012, 26, 609.1.	0.5	0
97	Diagnosis and monitoring of mucopolysaccharidoses using diseaseâ€specific nonâ€reducing end carbohydrate biomarkers. FASEB Journal, 2012, 26, 472.3.	0.5	0
98	Heparan Sulfate Proteoglycans. Cold Spring Harbor Perspectives in Biology, 2011, 3, a004952-a004952.	5.5	1,147
99	Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones. Bone, 2011, 48, 979-987.	2.9	57
100	Stage-dependent regulation of mammary ductal branching by heparan sulfate and HGF-cMet signaling. Developmental Biology, 2011, 355, 394-403.	2.0	46
101	Asparagine 405 of heparin lyase II prevents the cleavage of glycosidic linkages proximate to a 3â€ <i>O</i> â€sulfoglucosamine residue. FEBS Letters, 2011, 585, 2461-2466.	2.8	18
102	Differential Effects of Murine and Human Factor X on Adenovirus Transduction via Cell-surface Heparan Sulfate. Journal of Biological Chemistry, 2011, 286, 24535-24543.	3.4	17
103	Heparan Sulfate Is Essential for High Mobility Group Protein 1 (HMGB1) Signaling by the Receptor for Advanced Glycation End Products (RAGE). Journal of Biological Chemistry, 2011, 286, 41736-41744.	3.4	77
104	Lacrimal Gland Development and Fgf10-Fgfr2b Signaling Are Controlled by 2-O- and 6-O-sulfated Heparan Sulfate. Journal of Biological Chemistry, 2011, 286, 14435-14444.	3.4	72
105	Heparan Sulfate Regulates VEGF165- and VEGF121-mediated Vascular Hyperpermeability. Journal of Biological Chemistry, 2011, 286, 737-745.	3.4	80
106	Inhibitory Peptides of the Sulfotransferase Domain of the Heparan Sulfate Enzyme, N-Deacetylase-N-sulfotransferase-1. Journal of Biological Chemistry, 2011, 286, 5338-5346.	3.4	27
107	Secondary Storage of Dermatan Sulfate in Sanfilippo Disease. Journal of Biological Chemistry, 2011, 286, 6955-6962.	3.4	46
108	Glycosaminoglycan Binding Facilitates Entry of a Bacterial Pathogen into Central Nervous Systems. PLoS Pathogens, 2011, 7, e1002082.	4.7	50

JEFFREY D ESKO

#	Article	IF	CITATIONS
109	Cooperative, Heparan Sulfateâ€Đependent Cellular Uptake of Dimeric Guanidinoglycosides. ChemBioChem, 2010, 11, 2302-2310.	2.6	29
110	Loss of the Heparan Sulfate Sulfotransferase, Ndst1, in Mammary Epithelial Cells Selectively Blocks Lobuloalveolar Development in Mice. PLoS ONE, 2010, 5, e10691.	2.5	36
111	Deletion of the Basement Membrane Heparan Sulfate Proteoglycan Type XVIII Collagen Causes Hypertriglyceridemia in Mice and Humans. PLoS ONE, 2010, 5, e13919.	2.5	46
112	Heparan Sulfate 2-O-Sulfotransferase Is Required for Triglyceride-rich Lipoprotein Clearance*. Journal of Biological Chemistry, 2010, 285, 286-294.	3.4	76
113	Insulin-dependent Diabetes Mellitus in Mice Does Not Alter Liver Heparan Sulfate. Journal of Biological Chemistry, 2010, 285, 14658-14662.	3.4	16
114	Guanidinylated Neomycin Mediates Heparan Sulfate–dependent Transport of Active Enzymes to Lysosomes. Molecular Therapy, 2010, 18, 1268-1274.	8.2	32
115	Hepatic Heparan Sulfate Proteoglycans and Endocytic Clearance of Triglyceride-Rich Lipoproteins. Progress in Molecular Biology and Translational Science, 2010, 93, 213-233.	1.7	42
116	Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. Journal of Molecular and Cellular Cardiology, 2010, 49, 287-293.	1.9	22
117	Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. Journal of Clinical Investigation, 2009, 119, 3236-45.	8.2	176
118	Deficiency of Endothelial Heparan Sulfates Attenuates Allergic Airway Inflammation. Journal of Immunology, 2009, 183, 3971-3979.	0.8	48
119	Differentiation of 3-O-sulfated heparin disaccharide isomers: Identification of structural aspects of the heparin CCL2 binding motif. Journal of the American Society for Mass Spectrometry, 2009, 20, 652-657.	2.8	24
120	Symbol nomenclature for glycan representation. Proteomics, 2009, 9, 5398-5399.	2.2	162
121	A Golgi-on-a-chip for glycan synthesis. Nature Chemical Biology, 2009, 5, 612-613.	8.0	14
122	Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nature Methods, 2008, 5, 291-292.	19.0	130
123	Surfen, a small molecule antagonist of heparan sulfate. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13075-13080.	7.1	152
124	Altered Heparan Sulfate Structure in Mice with Deleted NDST3 Gene Function. Journal of Biological Chemistry, 2008, 283, 16885-16894.	3.4	63
125	Evolutionary Differences in Glycosaminoglycan Fine Structure Detected by Quantitative Glycan Reductive Isotope Labeling. Journal of Biological Chemistry, 2008, 283, 33674-33684.	3.4	170
126	Abnormal Patterns of Lipoprotein Lipase Release into the Plasma in GPIHBP1-deficient Mice. Journal of Biological Chemistry, 2008, 283, 34511-34518.	3.4	64

#	Article	lF	CITATIONS
127	Bud specific N-sulfation of heparan sulfate regulates <i>Shp2</i> -dependent FGF signaling during lacrimal gland induction. Development (Cambridge), 2008, 135, 301-310.	2.5	91
128	Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Current Opinion in Lipidology, 2008, 19, 307-313.	2.7	47
129	Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. Journal of Clinical Investigation, 2008, 118, 229-238.	8.2	131
130	Guanidinylated Neomycin Delivers Large, Bioactive Cargo into Cells through a Heparan Sulfate-dependent Pathway. Journal of Biological Chemistry, 2007, 282, 13585-13591.	3.4	69
131	Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. Journal of Cell Biology, 2007, 177, 539-549.	5.2	107
132	Human Xylosyltransferase II Is Involved in the Biosynthesis of the Uniform Tetrasaccharide Linkage Region in Chondroitin Sulfate and Heparan Sulfate Proteoglycans*. Journal of Biological Chemistry, 2007, 282, 5201-5206.	3.4	91
133	Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. Journal of Clinical Investigation, 2007, 117, 153-164.	8.2	177
134	Glycan Antagonists and Inhibitors: A Fount for Drug Discovery. Critical Reviews in Biochemistry and Molecular Biology, 2007, 42, 481-515.	5.2	75
135	Essential Alterations of Heparan Sulfate During the Differentiation of Embryonic Stem Cells to Sox1-Enhanced Green Fluorescent Protein-Expressing Neural Progenitor Cells. Stem Cells, 2007, 25, 1913-1923.	3.2	126
136	Heparan sulfate Ndst1 gene function variably regulates multiple signaling pathways during mouse development. Developmental Dynamics, 2007, 236, 556-563.	1.8	62
137	Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature, 2007, 446, 1030-1037.	27.8	1,413
138	Synthesis and biological evaluation of gem-diamine 1-N-iminosugars related to l-iduronic acid as inhibitors of heparan sulfate 2-O-sulfotransferase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 532-536.	2.2	27
139	CHO Glycosylation Mutants: Proteoglycans. Methods in Enzymology, 2006, 416, 205-221.	1.0	47
140	A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology, 2006, 16, 117-131.	2.5	161
141	Identification of novel chondroitin proteoglycans in Caenorhabditis elegans: embryonic cell division depends on CPG-1 and CPG-2. Journal of Cell Biology, 2006, 173, 985-994.	5.2	109
142	Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development (Cambridge), 2006, 133, 4933-4944.	2.5	96
143	Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nature Immunology, 2005, 6, 902-910.	14.5	424
144	The sweet and sour of cancer: glycans as novel therapeutic targets. Nature Reviews Cancer, 2005, 5, 526-542.	28.4	1,225

#	Article	IF	CITATIONS
145	The elusive role of heparan sulfate in Toxoplasma gondii infection. Molecular and Biochemical Parasitology, 2005, 139, 267-269.	1.1	7
146	Cell Surface Heparan Sulfate Promotes Replication of <i>Toxoplasma gondii</i> . Infection and Immunity, 2005, 73, 5395-5401.	2.2	23
147	Heparan 2-O-sulfotransferase, hst-2, is essential for normal cell migration in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1507-1512.	7.1	78
148	Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development (Cambridge), 2005, 132, 5055-5068.	2.5	221
149	Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development (Cambridge), 2005, 132, 3777-3786.	2.5	176
150	Temperature-sensitive Glycosaminoglycan Biosynthesis in a Chinese Hamster Ovary Cell Mutant Containing a Point Mutation in Glucuronyltransferase I. Journal of Biological Chemistry, 2004, 279, 5693-5698.	3.4	5
151	Stem domains of heparan sulfate 6-O-sulfotransferase are required for Golgi localization, oligomer formation and enzyme activity. Journal of Cell Science, 2004, 117, 3331-3341.	2.0	34
152	The differentiation of ES cells into neuroectodermal precursors is associated with an increase in the levels and sulfation of heparan sulfate proteoglycans. International Journal of Experimental Pathology, 2004, 85, A65-A66.	1.3	0
153	Proteoglycans. , 2004, , 549-555.		0
154	Synthesis of N-Acetyllactosamine Derivatives with Variation in the Aglycon Moiety for the Study of Inhibition of Sialyl Lewis x Expression. ChemBioChem, 2003, 4, 835-840.	2.6	22
155	Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis. Nature, 2003, 423, 439-443.	27.8	205
156	The Caenorhabditis elegans Genes sqv-2and sqv-6, Which Are Required for Vulval Morphogenesis, Encode Glycosaminoglycan Galactosyltransferase II and Xylosyltransferase. Journal of Biological Chemistry, 2003, 278, 11735-11738.	3.4	75
157	Regulated Translation of Heparan SulfateN-Acetylglucosamine N-Deacetylase/N-Sulfotransferase Isozymes by Structured 5′-Untranslated Regions and Internal Ribosome Entry Sites. Journal of Biological Chemistry, 2002, 277, 30699-30706.	3.4	67
158	Tumor attenuation by combined heparan sulfate and polyamine depletion. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 371-376.	7.1	114
159	Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate. Annual Review of Biochemistry, 2002, 71, 435-471.	11.1	1,367
160	Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochimica Et Biophysica Acta - General Subjects, 2002, 1573, 209-215.	2.4	143
161	Hereditary multiple exostoses and heparan sulfate polymerization. Biochimica Et Biophysica Acta - General Subjects, 2002, 1573, 346-355.	2.4	157
162	Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. Journal of Clinical Investigation, 2002, 110, 127-136.	8.2	258

#	Article	IF	CITATIONS
163	Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. Journal of Clinical Investigation, 2002, 110, 127-136.	8.2	163
164	Etiological Point Mutations in the Hereditary Multiple Exostoses Gene EXT1: A Functional Analysis of Heparan Sulfate Polymerase Activity. American Journal of Human Genetics, 2001, 69, 55-66.	6.2	71
165	Biosynthesis of the Linkage Region of Glycosaminoglycans. Journal of Biological Chemistry, 2001, 276, 48189-48195.	3.4	158
166	Cloning, Golgi Localization, and Enzyme Activity of the Full-length Heparin/Heparan Sulfate-Glucuronic Acid C5-epimerase. Journal of Biological Chemistry, 2001, 276, 21538-21543.	3.4	50
167	Multiple Isozymes of Heparan Sulfate/Heparin GlcNAcN-Deacetylase/GlcN N-Sulfotransferase. Journal of Biological Chemistry, 2001, 276, 5876-5882.	3.4	203
168	The Effect of Precursor Structures on the Action of Glucosaminyl 3-O-Sulfotransferase-1 and the Biosynthesis of Anticoagulant Heparan Sulfate. Journal of Biological Chemistry, 2001, 276, 28806-28813.	3.4	65
169	Molecular diversity of heparan sulfate. Journal of Clinical Investigation, 2001, 108, 169-173.	8.2	767
170	Synthesis and glycan priming activity of acetylated disaccharides. Carbohydrate Research, 2000, 329, 287-300.	2.3	42
171	Location of the Glucuronosyltransferase Domain in the Heparan Sulfate Copolymerase EXT1 by Analysis of Chinese Hamster Ovary Cell Mutants. Journal of Biological Chemistry, 2000, 275, 27733-27740.	3.4	74
172	Disruption of Gastrulation and Heparan Sulfate Biosynthesis in EXT1-Deficient Mice. Developmental Biology, 2000, 224, 299-311.	2.0	370
173	Chinese Hamster Ovary Cell Mutants Defective in Glycosaminoglycan Assembly and Glucuronosyltransferase I. Journal of Biological Chemistry, 1999, 274, 13017-13024.	3.4	101
174	Formation of HNK-1 Determinants and the Glycosaminoglycan Tetrasaccharide Linkage Region by UDP-GlcUA:Galactose β1,3-Glucuronosyltransferases. Journal of Biological Chemistry, 1999, 274, 7857-7864.	3.4	52
175	Molecular Cloning and Expression of a Third Member of the Heparan Sulfate/Heparin GlcNAcN-Deacetylase/N-Sulfotransferase Family. Journal of Biological Chemistry, 1999, 274, 2690-2695.	3.4	140
176	A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry. Cell, 1999, 99, 13-22.	28.9	948
177	Glycoside Primers ofPsittacanthus cucullaris. Journal of Natural Products, 1999, 62, 1036-1038.	3.0	21
178	Fucosylation of Disaccharide Precursors of Sialyl LewisX Inhibit Selectin-mediated Cell Adhesion. Journal of Biological Chemistry, 1997, 272, 25608-25616.	3.4	92
179	Turnover of Heparan Sulfate Depends on 2-O-Sulfation of Uronic Acids. Journal of Biological Chemistry, 1997, 272, 23172-23179.	3.4	68
180	Partial purification and substrate specificity of heparan sulfate α-N-acetylglucosaminyltransferase I: synthesis, NMR spectroscopic characterization and in vitro assays of two aryl tetrasaccharides. Glycobiology, 1997, 7, 587-595.	2.5	20

#	Article	IF	CITATIONS
181	Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature Medicine, 1997, 3, 866-871.	30.7	914
182	Influence of core protein sequence on glycosaminoglycan assembly. Current Opinion in Structural Biology, 1996, 6, 663-670.	5.7	179
183	An Animal Cell Mutant Defective in Heparan Sulfate Hexuronic Acid 2Sulfation. Journal of Biological Chemistry, 1996, 271, 17711-17717.	3.4	129
184	Heparan sulfate primed on β-D-xylosides restores binding of basic fibroblast growth factor. Journal of Cellular Biochemistry, 1995, 57, 173-184.	2.6	33
185	Accumulation of a Pentasaccharide Terminating in α-N-Acetylglucosamine in an Animal Cell Mutant Defective in Heparan Sulfate Biosynthesis. Journal of Biological Chemistry, 1995, 270, 12557-12562.	3.4	15
186	Repetitive Ser-Gly Sequences Enhance Heparan Sulfate Assembly in Proteoglycans. Journal of Biological Chemistry, 1995, 270, 27127-27135.	3.4	127
187	Special Considerations for Proteoglycans and Glycosaminoglycans and Their Purification. Current Protocols in Molecular Biology, 1993, 22, Unit17.2.	2.9	11
188	Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell, 1991, 64, 841-848.	28.9	2,430
189	Secretory heparin in murine mastocytoma cell lines. Biochemical Society Transactions, 1990, 18, 807-809.	3.4	4